CTLA4 and Miyoshi myopathy: Immune-suppressive cells, such as Tregs, TAMs, and MDSCs, and immune inhibitory pathways, including the programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) pathway and the cytotoxic T lymphocyte-associated protein 4 (CTLA-4) pathway, could hamper DC-based immunotherapy, causing insufficient clinical responses in MM [150].